Hemophilia A Clinical Trials in Tianjin, Tianjin Municipality
9 recruitingTianjin, Tianjin Municipality, China
Showing 1–9 of 9 trials
Recruiting
Phase 3
Safety of KN057 Prophylaxis in Patients With Haemophilia A or B
Hemophilia A or B
Suzhou Alphamab Co., Ltd.70 enrolled1 locationNCT07545395
Recruiting
Phase 3
Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
Hemophilia AHemophilia B
Pfizer245 enrolled75 locationsNCT05145127
Recruiting
Phase 3
A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
Hemophilia AHemophilia B
Pfizer100 enrolled66 locationsNCT05611801
Recruiting
Phase 2Phase 3
Evaluation of the Safety and Efficacy of Hemophilia A Gene Therapy Drugs
Hemophilia A
Shanghai Xinzhi BioMed Co., Ltd.55 enrolled10 locationsNCT06111638
Recruiting
National Longitudinal Cohort of Hematological Diseases
Acute Myeloid LeukemiaMultiple MyelomaMyelodysplastic Syndrome+14 more
Institute of Hematology & Blood Diseases Hospital, China2,300 enrolled1 locationNCT04645199
Recruiting
Phase 3
To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A
Hemophilia A
Gritgen Therapeutics Co., Ltd.50 enrolled13 locationsNCT06833983
Recruiting
Not Applicable
Gene Therapy for Chinese Hemophilia A
Hemophilia AGene Therapy
Institute of Hematology & Blood Diseases Hospital, China12 enrolled1 locationNCT04728841
Recruiting
Early Phase 1
Safety and Efficacy Study of NGGT003 in Hemophilia A Patients
Hemophilia A
Institute of Hematology & Blood Diseases Hospital, China6 enrolled1 locationNCT06238908
Recruiting
Early Phase 1
A Study of FVIII Gene Therapy for Hemophilia A
Hemophilia A
Institute of Hematology & Blood Diseases Hospital, China8 enrolled1 locationNCT05454774